  HBV surface antigen ( HBsAg) reduction is well observed in chronic hepatitis<disease> B<disease> ( CHB) patients treated with pegylated interferon alpha-2a ( PegIFNα). However , the mechanism of HBsAg suppression has not been fully elucidated. Twenty-seven of 55 entecavir-treated CHB e antigen positive patients were switched to PegIFNα treatment ( Group A) whereas 28 patients continued entecavir treatment ( Group B). The percentage or absolute number of CD56